<p><strong>荷兰莱顿，2025 年 12 月 8 日：</strong> Pharming Group N.V.（“Pharming”）（Euronext Amsterdam: PHARM/Nasdaq: PHAR）今天宣布将参加于 2025 年 12 月 11 日在纽约市举行的 Oppenheimer 罕见疾病峰会。该活动仅限受邀参加，汇聚了专注于罕见疾病的创新公司和投资者。</p>
<p>Pharming 的首席医学官 Anurag Relan 博士将于东部时间下午 1:50 / 中欧时间晚上 7:50 参与一场关于遗传性血管神经性水肿（HAE）市场的炉边谈话。</p>
<p>如需与 Pharming 管理团队安排一对一会议，请联系投资者关系部，邮箱为 investor@pharming.com 或您的 Oppenheimer 代表。</p>
<p><strong>关于 Pharming Group N.V.</strong></p>
<p>Pharming Group N.V.（EURONEXT Amsterdam: PHARM/Nasdaq: PHAR）是一家全球生物制药公司，致力于改善罕见、致残和危及生命疾病患者的生活。我们正在开发和商业化一系列创新药物，包括小分子和生物制剂。Pharming 总部位于荷兰莱顿，且其员工中有相当一部分位于美国。</p>
<p>欲了解更多信息，请访问 www.pharming.com 并在 LinkedIn 上关注我们。</p>
<p><strong>如需进一步公共信息，请联系：</strong></p>
<p><strong>投资者关系</strong></p>
<p>Michael Levitan，投资者关系与企业传播副总裁</p>
<p>电话：+1 (908) 705 1696</p>
<p>邮箱：investor@pharming.com</p>
<p><strong>媒体关系</strong></p>
<p>全球：Saskia Mehring，企业传播经理</p>
<p>电话：+31 6 28 32 60 41</p>
<p>邮箱：media.relations@pharming.com</p>
<p>美国：Ethan Metelenis（代表 Pharming 的 Precision AQ）</p>
<p>电话：+1 (917) 882-9038</p>
<p>荷兰：Leon Melens（代表 Pharming 的 LifeSpring 生命科学传播）</p>
<p>电话：+31 6 53 81 64 27</p>
<ul>
<li>Pharming Oppenheimer Movers in Rare Disease Conference_EN_08DEC25</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9TVRBd01URTBNelEyTXlNME1ESXlOemt4TmpVak1qQXdNRGszTmc9PQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9TVRBd01URTBNelEyTXlNME1ESXlOemt4TmpVak1qQXdNRGszTmc9PQ"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml-eu.globenewswire.com/media/MmQxNmJjMTQtZWJlOC00MTFiLWFlNDAtYjNlOWE3YmQyMGQ4LTEwMTI1NDktMjAyNS0xMi0wOC1lbg==/tiny/Pharming-Group-N-V-.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://ml-eu.globenewswire.com/media/MmQxNmJjMTQtZWJlOC00MTFiLWFlNDAtYjNlOWE3YmQyMGQ4LTEwMTI1NDktMjAyNS0xMi0wOC1lbg==/tiny/Pharming-Group-N-V-.png"/></p>

PHAR

<p>Pharming Group N.V. 将于 2025 年 12 月 11 日在纽约市参加 Oppenheimer 罕见疾病峰会。首席医学官 Anurag Relan 将讨论遗传性血管性水肿市场。该活动为邀请制，汇聚了在罕见疾病领域的创新公司和投资者。Pharming 是一家专注于罕见、致残性疾病的生物制药公司</p>

<p><strong>Leiden, the</strong> <strong>Netherlands, December 8, 2025:</strong> Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) today announced its participation in the Oppenheimer Movers in Rare Disease Summit on December 11, 2025 in New York City. This invitation-only event brings together innovative companies and investors focused on rare diseases.</p>
<div class="lb-trans"><p><strong>荷兰莱顿，2025 年 12 月 8 日：</strong> Pharming Group N.V.（“Pharming”）（Euronext Amsterdam: PHARM/Nasdaq: PHAR）今天宣布将参加于 2025 年 12 月 11 日在纽约市举行的 Oppenheimer 罕见疾病峰会。该活动仅限受邀参加，汇聚了专注于罕见疾病的创新公司和投资者。</p>
</div><p>Anurag Relan, M.D., Chief Medical Officer of Pharming, will participate in a fireside chat focused on the hereditary angioedema (HAE) market at 1:50 pm ET / 19:50 CET.</p>
<div class="lb-trans"><p>Pharming 的首席医学官 Anurag Relan 博士将于东部时间下午 1:50 / 中欧时间晚上 7:50 参与一场关于遗传性血管神经性水肿（HAE）市场的炉边谈话。</p>
</div><p>To schedule a one-on-one meeting with Pharming’s management team, please contact Investor Relations at investor@pharming.com or your Oppenheimer representative.</p>
<div class="lb-trans"><p>如需与 Pharming 管理团队安排一对一会议，请联系投资者关系部，邮箱为 investor@pharming.com 或您的 Oppenheimer 代表。</p>
</div><p><strong>About Pharming Group N.V.</strong></p>
<div class="lb-trans"><p><strong>关于 Pharming Group N.V.</strong></p>
</div><p>Pharming Group N.V. (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. We are developing and commercializing a portfolio of innovative medicines, including small molecules and biologics. Pharming is headquartered in Leiden, the Netherlands, with a significant proportion of its employees based in the U.S.</p>
<div class="lb-trans"><p>Pharming Group N.V.（EURONEXT Amsterdam: PHARM/Nasdaq: PHAR）是一家全球生物制药公司，致力于改善罕见、致残和危及生命疾病患者的生活。我们正在开发和商业化一系列创新药物，包括小分子和生物制剂。Pharming 总部位于荷兰莱顿，且其员工中有相当一部分位于美国。</p>
</div><p>For more information, visit www.pharming.com and find us on LinkedIn.</p>
<div class="lb-trans"><p>欲了解更多信息，请访问 www.pharming.com 并在 LinkedIn 上关注我们。</p>
</div><p><strong>For further public information, contact:</strong></p>
<div class="lb-trans"><p><strong>如需进一步公共信息，请联系：</strong></p>
</div><p><strong>Investor Relations</strong></p>
<div class="lb-trans"><p><strong>投资者关系</strong></p>
</div><p>Michael Levitan, VP Investor Relations &amp; Corporate Communications</p>
<div class="lb-trans"><p>Michael Levitan，投资者关系与企业传播副总裁</p>
</div><p>T: +1 (908) 705 1696</p>
<div class="lb-trans"><p>电话：+1 (908) 705 1696</p>
</div><p>E: investor@pharming.com</p>
<div class="lb-trans"><p>邮箱：investor@pharming.com</p>
</div><p><strong>Media Relations</strong></p>
<div class="lb-trans"><p><strong>媒体关系</strong></p>
</div><p>Global: Saskia Mehring, Corporate Communications Manager</p>
<div class="lb-trans"><p>全球：Saskia Mehring，企业传播经理</p>
</div><p>T: +31 6 28 32 60 41</p>
<div class="lb-trans"><p>电话：+31 6 28 32 60 41</p>
</div><p>E: media.relations@pharming.com</p>
<div class="lb-trans"><p>邮箱：media.relations@pharming.com</p>
</div><p>U.S.: Ethan Metelenis (Precision AQ on behalf of Pharming)</p>
<div class="lb-trans"><p>美国：Ethan Metelenis（代表 Pharming 的 Precision AQ）</p>
</div><p>T: +1 (917) 882-9038</p>
<div class="lb-trans"><p>电话：+1 (917) 882-9038</p>
</div><p>Netherlands: Leon Melens (LifeSpring Life Sciences Communication on behalf of Pharming)</p>
<div class="lb-trans"><p>荷兰：Leon Melens（代表 Pharming 的 LifeSpring 生命科学传播）</p>
</div><p>T: +31 6 53 81 64 27</p>
<div class="lb-trans"><p>电话：+31 6 53 81 64 27</p>
</div><ul>
<li>Pharming Oppenheimer Movers in Rare Disease Conference_EN_08DEC25</li>
</ul>
<div class="lb-trans"><ul>
<li>Pharming Oppenheimer Movers in Rare Disease Conference_EN_08DEC25</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9TVRBd01URTBNelEyTXlNME1ESXlOemt4TmpVak1qQXdNRGszTmc9PQ" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=MTAwMTE0MzQ2MyM0MDIyNzkxNjUjMjAwMDk3Ng=="/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml-eu.globenewswire.com/media/MmQxNmJjMTQtZWJlOC00MTFiLWFlNDAtYjNlOWE3YmQyMGQ4LTEwMTI1NDktMjAyNS0xMi0wOC1lbg==/tiny/Pharming-Group-N-V-.png" alt="" original-src="https://ml-eu.globenewswire.com/media/MmQxNmJjMTQtZWJlOC00MTFiLWFlNDAtYjNlOWE3YmQyMGQ4LTEwMTI1NDktMjAyNS0xMi0wOC1lbg==/tiny/Pharming-Group-N-V-.png"/></p>

Pharming Group 将参与 Oppenheimer 罕见病峰会 | PHARM 股票新闻